Category Archives: Stem Cells

The report on the Covid-19 Impact on Stem Cells Cryopreservation Equipments market provides a birds eye view of the current proceeding within the Covid-19 Impact on Stem Cells Cryopreservation Equipments market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Covid-19 Impact on Stem Cells Cryopreservation Equipments market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Covid-19 Impact on Stem Cells Cryopreservation Equipments market over the forecast period (2020-2026) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

Covid-19 Impact on Stem Cells Cryopreservation Equipments Market report provides in-depth review of the Expansion Drivers, Potential Challenges, Distinctive Trends, and Opportunities for market participants equip readers to totally comprehend the landscape of the Covid-19 Impact on Stem Cells Cryopreservation Equipments market. Major prime key manufactures enclosed within the report alongside Market Share, Stock Determinations and Figures, Contact information, Sales, Capacity, Production, Price, Cost, Revenue and Business Profiles are (Chart,Worthington Industries,Cesca Therapeutics,Shengjie Cryogenic Equipment,Sichuan Mountain Vertical,Qingdao Beol,). The main objective of the Covid-19 Impact on Stem Cells Cryopreservation Equipments industry report is to Supply Key Insights on Competition Positioning, Current Trends, Market Potential, Growth Rates, and Alternative Relevant Statistics.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Covid-19 Impact on Stem Cells Cryopreservation Equipments Market Report @ https://www.researchmoz.us/enquiry.php?type=S&repid2643020

Covid-19 Impact on Stem Cells Cryopreservation Equipments Market By Capability, Production and Share By Manufacturers, Top 3 and Top 5 Manufacturers,Covid-19 Impact on Stem Cells Cryopreservation Equipments Market Share of Manufacturers, Revenue and Share By Manufacturers, Producing Base Distribution, Sales Area, Product Kind, Market Competitive Scenario And Trends, Market Concentration Rate.

Later, the report gives detailed analysis about the major factors fuelling the expansion of Covid-19 Impact on Stem Cells Cryopreservation Equipments Market in the coming years. Some of the major factors driving the growth of Covid-19 Impact on Stem Cells Cryopreservation Equipments Market are-

Covid-19 Impact on Stem Cells Cryopreservation Equipments Market Regional Analysis Includes:

Moving forward, the researched report gives details about the strategies applied by companies as well as new entrants to expand its presence in the market.On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, sales volume, Covid-19 Impact on Stem Cells Cryopreservation Equipments market share and growth rate of Covid-19 Impact on Stem Cells Cryopreservation Equipments foreach application, including-

On the basis of product,this report displays the sales volume, revenue (Million USD), product price, Covid-19 Impact on Stem Cells Cryopreservation Equipments market share and growth rate ofeach type, primarily split into-

The market study report also fragments the market on basis regions and sub regions. Furthermore, discusses the contribution of major regions that are likely to influence the market in the coming years.

Key Questions Answered in the Report:-

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://www.researchmoz.us/enquiry.php?type=E&repid2643020

Some of the Major Highlights of TOC covers:

For More Information Kindly Contact: ResearchMozMr. Rohit Bhisey,90 State Street,Albany NY,United States 12207Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email: [emailprotected]Media Release @ https://www.researchmoz.us/pressreleaseFollow me on Blogger: https://trendingrelease.blogspot.com/

See more here:
Covid-19 Impact on Stem Cells Cryopreservation Equipments Market Business Intelligence and Forecast By 2020-2026 - Cole of Duty

The report provides insights on opportunities, restraints, drivers, trends, and forecasts up to 2028. As per the over view of the globalStem cells marketthe market was at US$ xx mn in 2019 and is expected grow at a CAGR of xx% over the forecast period 2016 2028. The detailed study of the business of the Stem cells market covers the estimation size of the market in terms of volume and value.

In an attempt to identify the opportunities for growth in the Stem cells market, the industry analysis was geographically divided into significant regions that are progressing faster than the overall market.

Each market player included in the study of Stem cells market is evaluated according to its production footprint, market share, existing and new launches, current R&D projects, and business strategies. Also, the Stem cells market study evaluates the strengths, weaknesses, opportunities and threats (SWOT) analysis. The report evaluates and explores the progress outlook for the global Stem cells market environment, including sales, production & usage and historical data & forecasting.

For more information, download sample of the premium report:https://www.quincemarketinsights.com/request-sample-60762?utm_source=campaign=Pooja/3WN

ThisPress Release will help you to understand the size, growth opportunities with Trends that control the market.

What insights will readers obtain from the report on the Stem cells market?

This report is customized by segment, by sub-segment, by region/country, along with a product specific competitive analysis to meet your specific requirements.

Important objectives of this report are:To estimate the market size for Stem cells market on a regional and global basis, to identify major segments in Stem cells market and evaluate their market shares and demand, to provide a competitive scenario for the Stem cells market with major developments observed by key companies in the historic years, and to evaluate key factors governing the dynamics of the Stem cells market with their potential gravity during the forecast period.

The Key Players mentioned in our report are: BioTime Inc., Cytori Therapeutics, Inc., STEMCELL Technologies Inc., Astellas Pharma Inc., U.S. Stem Cell, Inc., Osiris Therapeutics, Inc., Takara Bio Inc., Caladrius Biosciences, Inc., Cellular Engineering Technologies Inc., BrainStorm Cell Therapeutics Inc.

Get ToC for the overview of the premium report:https://www.quincemarketinsights.com/request-toc-60762?utm_source=campaign=Pooja/3WN

Market Segmentation:

By Product:

Adult Stem Cell

Human Embryonic Stem Cell

Induced Pluripotent Stem Cell

By Sources:

Autologous

Allogeneic

By Application:

Regenerative Medicine

Drug Discovery & Development

By End-Users:

Therapeutic Companies

Cell & Tissues Banks

Tools & Reagent Companies

Service Companies

By Region:

North America

North America, by Country

US

Canada

Mexico

North America, by Product

North America, by Sources

North America, by Application

North America, by End-Users

Western Europe

Western Europe, by Country

Germany

UK

France

Italy

Spain

The Netherlands

Rest of Western Europe

Western Europe, by Product

Western Europe, by Sources

Western Europe, by Application

Western Europe, by End-Users

Asia Pacific

Asia Pacific, by Country

China

India

Japan

South Korea

Australia

Indonesia

Rest of Asia Pacific

Asia Pacific, by Product

Asia Pacific, by Sources

Asia Pacific, by Application

Asia Pacific, by End-Users

Eastern Europe

Eastern Europe, by Country

Russia

Turkey

Rest of Eastern Europe

Eastern Europe, by Product

Eastern Europe, by Sources

Eastern Europe, by Application

Eastern Europe, by End-Users

Middle East

Middle East, by Country

UAE

Saudi Arabia

Qatar

Iran

Rest of Middle East

Middle East, by Product

Middle East, by Sources

iddle East, by Application

Middle East, by End-Users

Rest of the World

Rest of the World, by Country

South America

Africa

Rest of the World, by Product

Rest of the World, by Sources

Rest of the World, by Application

Rest of the World, by End-Users

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact UsQuince Market InsightsAjay D. (Knowledge Partner)Office No- A109,Pune, Maharashtra 411028Phone: +91 706 672 5858/+1 208 405 2835/+91 706 672 4848Email:[emailprotected]Web:www.quincemarketinsights.com

Read more:
Stem Cells Market Analysis Growth Opportunities and Demand Drives by 2016 to 2028 - 3rd Watch News

The COVID-19 pandemic has been a shock for most people, but for Clay Drake, much of it was familiar: the need to stay in, the stocking up on hand sanitizer, the concern that a simple trip to church could turn deadly.

Drake, of Windsor, has multiple myeloma, a blood cell cancer, and underwent two stem cell transplants that knocked out his immune system for months. A bout with the seasonal flu lasted more than a month, and for a while he was getting colds that took him weeks to shake, he said.

That was my COVID, he said. I spent probably about a year doing what everybody started doing in March.

While many though not all healthy people who get COVID-19 can recover at home, those who have chronic conditions are six times as likely to be hospitalized and 12 times as likely to die, according to a report from the Centers for Disease Control and Prevention.

Drake still gets chemotherapy and immunotherapy treatments to keep the cancer in remission. Because of the heightened risk from infections, he tries to minimize trips to crowded places but has started seeing small groups of friends again and occasionally eating out. Most people around Windsor seem to be wearing masks and following other recommendations, which makes it safer, he said.

For the most part, I feel comfortable going out in public, he said.

People who have chronic conditions need to be vigilant about social distancing, wearing a mask and washing their hands, according to the CDC, and should talk to their doctors about additional precautions.

While those who know they face a higher risk of dying can take some steps to protect themselves, the rest of the community also needs to help keep the virus from breaking out, said Dr. Peter Buttrick, a cardiologist and member of the board for the Denver branch of the American Heart Association. Most people who get the virus can spread it before developing symptoms, meaning they could inadvertently give it to someone whos at a higher risk especially if they arent wearing masks, he said.

The likelihood youll be in contact with someone who is infected and asymptomatic is higher when theres ongoing community spread, he said.

Colorados new cases are down from a peak in April, but theyve started to tick back up and Gov. Jared Polis has urged the public to continue avoiding large events and wearing masks.

The Centers for Disease Control and Prevention released an updated list Thursday of the clearest risk factors for getting severely sick or dying from COVID-19:

The CDC also listed other conditions as possible risk factors, though the evidence is mixed or from small studies:

A large study in the United Kingdom found that the risk of dying increased sharply with age, but younger people were also at a higher risk if they had certain conditions, said Dr. Jonathan Samet, dean of the Colorado School of Public Health. Diabetes and chronic lung conditions such as emphysema roughly doubled the risk of dying compared to a healthy person of the same age, and heart disease increased the risk by about 25%. Obesity also raised a persons risk of complications, he said.

About 7% of adults in Colorado have diabetes and 23% have obesity, which are some of the lowest rates in the country, according to Americas Health Rankings. Still, that means thousands of people are at an elevated risk, and not all of them may have the ability to stay at home. Ideally, those who are at a high risk would continue social distancing at a high level, Samet said.

Its certainly a time for caution, if peoples jobs and lives allow it, he said.

Not everyone with diabetes is at an equal risk, said Dr. Robert Gabbay, chief scientific and medical officer for the American Diabetes Association. People who have poorly controlled blood sugar and have other chronic conditions generally are at a higher risk from infections, including COVID-19. That makes it important to keep in touch with your doctor and to manage your diabetes well, he said.

If you have diabetes, you have high blood sugars, youre obese and you have maybe cardiovascular disease, youre at high risk and you need to be really careful, he said, adding that age also is a factor to consider.

Its not entirely clear why certain conditions are linked to a higher risk of complications. One possibility is that when hearts are stressed by high blood pressure or coronary artery disease, their cells produce more of certain receptors that the virus binds to though more research is needed to understand if thats the issue, Buttrick said. He urged people not to put off seeking medical advice if they have symptoms that could suggest heart trouble, such as chest pain, shortness of breath, heart palpitations or fainting not only because of the virus risk, but also because the problem itself may need immediate treatment.

Heart disease doesnt go on vacation during the pandemic, he said.

Buttrick and Samet dont advise people with chronic illnesses to stay at home at all times, but say they should consider ways to avoid crowds, like visiting the grocery store during hours set aside for high-risk customers. Ultimately, each patient and doctor need to discuss individual risks, though.

Im telling all of my patients, and I think everybody is, that if youre of a certain age, you need to be really careful, Buttrick said.

People with diabetes and other conditions have to consider their individual level of risk, as well as how risky any particular activity is, Gabbay said. If you have well-controlled blood sugar and no other chronic conditions, you might feel more comfortable going to a lower-risk social event, while someone whose health is more precarious might avoid any exposure that isnt absolutely necessary.

Thats whats made this so difficult there are no hard and fast rules, he said.

Hyoung Chang, The Denver Post

Drake, who volunteers with the American Cancer Society, said he sometimes gets calls from people trying to figure out what they should do, and he steers them toward the ACS guidelines. Some of them are particularly worried about how to move forward with cancer treatment during a pandemic, he said.

I feel like theres a lot of people, particularly the more susceptible and elderly, who are scared, he said.

Subscribe to bi-weekly newsletter to get health news sent straight to your inbox.

See the article here:
COVID threat isnt over, especially for Coloradans with chronic conditions - The Denver Post

Stem Cells Market Research Report provides customers with a complete analytical study that provides all the details of key players such as company profile, product portfolio, capacity, price, cost and revenue during the forecast period from 2020 to 2027. A Stem Cells market that includes Future Trends, Current Growth Factors, Meticulous Opinions, Facts, Historical Data and Statistically Supported And Industry-Validated Market Data.

This Stem Cells market research provides a clear explanation of how this market will make a growth impression during the mentioned period. This study report scanned specific data for specific characteristics such as Type, Size, Application and End User. There are basic segments included in the segmentation analysis that are the result of SWOT analysis and PESTEL analysis.

RequestSample PDF of Stem Cells Market Report https://www.worldwidemarketreports.com/sample/273624

Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCR Pharmaceutical, Pharmicell, Medi-post, Anterogen, MolMed, Takeda (TiGenix) are some of the major organizations dominating the global market.

(*Note: Other Players Can be Added per Request)

Key players in the Stem Cells market were identified through a second survey, and market share was determined through a first and second survey. All measurement sharing, splitting and analysis were solved using a secondary source and a validated primary source. The Stem Cells market report starts with a basic overview of the Industry Life Cycle, Definitions, Classifications, Applications, and Industry Chain Structure. The combination of these two factors will help key players meet the market reach and help to understand offered characteristics and customer needs.

The report also makes some important suggestions for the new Stem Cells market project before evaluating its feasibility. Overall, this report covers Stem Cells market Sales, Price, Sales, Gross Profit, Historical Growth and Future Prospects. It provides facts related to mergers, acquisitions, partnerships and joint venture activities prevalent in the market.

This report includes market size estimates of value (million US $) and volume (K MT). The top-down and bottom-up approaches are used to estimate and validate the market size of the Stem Cells market, estimating the size of various other submarkets in the overall market. Major players in the market were identified through secondary studies, and market share was determined through primary and secondary studies. All ratio sharing, splitting and analysis were determined using the secondary source and the identified primary source.

What Stem Cells Market report offers:

Regions Covered in This Report

Complete knowledge of the Stem Cells market is based on the latest industry news, opportunities and trends in the expected region. The Stem Cells market research report provides clear insights into the influential factors expected to change the global market in the near future.

Remarkable Attributes of Stem Cells Market Report:

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends.

See the rest here:
Stem Cells Market: After COVID 19 Will Industry Survive: Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals - Surfacing Magazine

The demand for Cryopreservation Equipment in Stem Cells Industry is anticipated to be high for the next six years. By considering this demand we provide latest Cryopreservation Equipment in Stem Cells Market Report which gives complete industry analysis, market outlook, size, growth and forecast till 2026. This report will assist in analyzing the current and future business trends, sales and revenue forecasts.

The Cryopreservation Equipment in Stem Cells market research report thoroughly analyzes this industry vertical while elaborating on the various market segmentations. Key aspects of the market including the current industry size as well as position as per revenue and volume predications are highlighted in the document. Furthermore, the report delivers information regarding the regional contribution as well as the competitive scenario of this business landscape.

This report shows the outstanding growth of Cryopreservation Equipment in Stem Cells market as well as increasing the Production Price Cost Production Value of Cryopreservation Equipment in Stem Cells Market. Given report is shows Export Market Analysis, main region analysis and upcoming demand of Cryopreservation Equipment in Stem Cells market.

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/223910

Underlining the primary details of the Cryopreservation Equipment in Stem Cells market report:

From the regional frame of reference:

Unveiling the competitive spectrum of the Cryopreservation Equipment in Stem Cells market:

Additional data highlighted in the research report:

Highlights following key factors:

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/223910

Go here to read the rest:
Research Report and Overview on Cryopreservation Equipment in Stem Cells Mark - News by aeresearch

The report delivers the driving factors, challenges, restraints, opportunities, acquisition & merger, revenue structure, business models, market players, segmentation, regional analysis, production price, manufacturing process, operations, methodology, market share, market size, CAGR, and investments.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4197303

Manufacturer Detail

Manufacturer DetailMedivet Biologics LLCVETSTEM BIOPHARMAJ-ARMU.S. Stem Cell, IncVetCell TherapeuticsCelavet Inc.Magellan Stem CellsKintaro Cells PowerAnimal Stem CareAnimal Cell TherapiesCell Therapy SciencesAnimacel

BIS reports covers key roles in analyzing the industry outlook and let understand the prominent vendors about their strategies and future plans for the betterment of the market in the near future. Furthermore, the report also covers an ultimate goal of market target gained on the basis of product or services. In this Animal Stem Cell Therapy market report, viewers can also experience detailed study of business introduction including benefits, restraints, opportunities, challenges, drivers, and more. The report smartly takes you to productive methodology in organizing, collection, and analyzing data. The report covers key aspects including production, market share, CAGR, key regions, leading vendors, and revenue rates. This keyword report also provides viewers with relevant figures at which the Animal Stem Cell Therapy market was valued in the base year and estimated to project the revenue in the forecasted period. The Animal Stem Cell Therapy market is categorizes several segmentations including type, application, end user industry, and region. This effective set of information delivers an in-depth analysis about the drivers, challenges, market share, market dynamics, emerging countries, pricing, investment activity, industry performance, revenue generation and CAGR.

Region Segmentation

North America Country (United States, Canada)South AmericaAsia Country (China, Japan, India, Korea)Europe Country (Germany, UK, France, Italy)Other Country (Middle East, Africa, GCC)

Product Type SegmentationAlN-170 AlN Ceramic SubstratesAlN-200 AlN Ceramic SubstratesOthers, like AlN-180 and AlN-230 etc.Industry SegmentationIGBTLED

Browse the complete report @ https://www.orbisresearch.com/reports/index/global-animal-stem-cell-therapy-market-report-2020

Channel (Direct Sales, Distributor) Segmentation

Section 8: 400 USDTrend (2019-2024)

Section 9: 300 USDProduct Type Detail

Section 10: 700 USDDownstream Consumer

Section 11: 200 USDCost Structure

Section 12: 500 USDConclusion

The research report is an overall draft when it comes to understand the investment structure and future analysis of the Animal Stem Cell Therapy market. BIS Report manages to convey detailed information regarding prominent vendors of the Animal Stem Cell Therapy market including recent innovations, advancements, improvements, business estimation, revenue margin, and sales graph.

Consumer-wise, the report studies about the demand coming from particular region and category of consumers taking interest in the product or services of the Animal Stem Cell Therapy market. The global keyword market is majorly driven by key factors and offers an in-depth insight about the keyword market.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4197303

The Animal Stem Cell Therapy market reports delivers the information about market competition between vendors through regional segmentation of markets in terms of business opportunities, demand & supply, and revenue generation potential.

BIS report envision clear view about Animal Stem Cell Therapy market including regional growth and falls down mentioning about particular forecast period along with appropriate reasoning about the market.

The Animal Stem Cell Therapy market also delivers the market size, market appearances, segmentation, provincial collapses, tendencies, competitive background to gain the appropriate insights. Moreover, the report also covers about the acquisitions and mergers taken in the recent past.

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us: Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155Email ID: [emailprotected]

Follow this link:
Global Animal Stem Cell Therapy Market Report 2020 Cole Reports - Cole of Duty

The frenetic search for the miracle that will rid the world of COVID-19 is branching out in a thousand directions, and a large part of the microbial treasure hunt is going on in the Bay Area, where major progress has been made in the 100 days since residents were ordered to shelter in place.

Scientists at universities, laboratories, biotechnology companies and drug manufacturers are combing through blood plasma taken from infected patients for secrets that will help them fight the disease.

The key is likely a super-strength antibody found in some patients. But researchers must first figure out how those antibodies work and how they can be harnessed and used to stop the many health problems associated with COVID-19, particularly acute respiratory distress syndrome, or ARDS, which has killed more people than any other complication connected to the disease.

Other developments showing promise include injections of mesenchymal stem cells, found in bone marrow and umbilical cords, that doctors are studying to battle inflammation caused by ARDS. And a steroid called dexamethasone reduced the number of deaths by halting the overreactive immune responses in seriously ill patients in the United Kingdom.

In all, more than 130 vaccines and 220 treatments are being tested worldwide.

What follows is a list of some of the most promising elixirs, medications and vaccines with ties to the Bay Area:

Monoclonal antibodies / Vir Biotechnology, San Francisco: Scientists at Vir and several institutions, including Stanford and UCSF, are studying monoclonal antibodies, which are clones of coronavirus-fighting antibodies produced by COVID-19 patients.

The idea is to utilize these neutralizing antibodies which bind to the virus crown-like spikes and prevent them from entering and hijacking human cells.

Only about 5% of coronavirus patients have these super-strength antibodies, and those people are believed to be immune to a second attack.

The trick for scientists at Vir is to identify these neutralizing antibodies, harvest, purify and clone them. If they succeed, the resulting monoclones could then be used to inoculate people and it is hoped give them long-term immunity against the coronavirus. The company recently signed a deal with Samsung Biologics, in South Korea, to scale up production of a temporary vaccine in the fall after clinical trials are complete.

Another monoclonal antibody, leronlimab, is being studied in coronavirus clinical trials by its Washington state drugmaker, CytoDyn. The companys chief medical officer is in San Francisco, and the company that does laboratory tests of leronlimab is in San Carlos.

Interferon-lambda / Stanford University: Doctors at Stanford are running a trial to see if interferon-lambda, which is administered by injection, helps patients in the early stages of COVID-19. Interferon-lambda is a manufactured version of a naturally occurring protein that has been used to treat hepatitis. Stanford doctors hope it will boost the immune system response to coronavirus infections.

Dr. Upinder Singh, a Stanford infectious-disease expert, said the trial has enrolled more than 50 patients and is halfway finished. We have noted that patients tolerate the drug very well, she said.

Mesenchymal stem cells / UCSF and UC Davis Medical Center: UCSF Dr. Michael Matthay is leading a study about whether a kind of stem cell found in bone marrow can help patients with ARDS. Matthay hopes that the stem cells can help reduce the inflammation associated with some of ARDS most dire respiratory symptoms, and help patients lungs to recover.

Matthay is aiming to enroll 120 patients in San Francisco, the UC Davis Medical Center in Sacramento and hospitals in a handful of other states. He said the trial, which includes a small number ARDS patients who dont have COVID-19, should have results within a year. So far 17 patients are enrolled in the trial, most of them in San Francisco.

Remdesivir / Gilead Sciences (Foster City): Remdesivir, once conceived as a potential treatment for ebola, was the first drug to show some promise in treating COVID-19 patients. The drug interferes with the process through which the virus replicates itself. A large study led by the federal government generated excitement in late April when officials said hospitalized patients who received remdesivir intravenously recovered faster than those who received a placebo.

A later study looking at dosage showed some benefit for moderately ill COVID-19 patients who received remdesivir for five days, but improvement among those who got it for 10 days was not statistically significant. Gilead, a drug company, recently announced that it will soon launch another clinical trial to see how remdesivir works on 50 pediatric patients, from newborns to teenagers, with moderate to severe COVID-19 symptoms. More than 30 locations in the U.S. and Europe will be involved in the trial, the company said.

Coronavirus crisis: 100 days

Editors note: Its been 100 days since the Bay Area sheltered in place, protecting itself from the coronavirus pandemic. What have we learned in that time? And what does the future hold for the region and its fight against COVID-19? The Chronicle explores the past 100 days and looks to the future in this exclusive report.

Favipiravir / Fujifilm Toyama Chemical (Stanford University): This antiviral drug, developed in 2014 by a subsidiary of the Japanese film company to treat influenza, is undergoing numerous clinical studies worldwide, including a Stanford University trial that began this month. Unlike remdesivir, it can be administered orally, so it can be used to treat patients early in the disease, before hospitalization is necessary.

Stanford epidemiologists want to see if favipiravir, which has shown promising results in other trials, prevents the coronavirus from replicating in human cells, halts the shedding of the virus and reduces the severity of infection. The Stanford study, the only outpatient trial for this drug in the nation, is enrolling 120 people who have been diagnosed with COVID-19 within the past 72 hours. Half of them will get a placebo. People can enroll by emailing treatcovid@stanford.edu.

Colchicine / UCSF (San Francisco and New York): The anti-inflammatory drug commonly used to treat gout flare-ups is being studied in the U.S. by scientists at UCSF and New York University. The drug short-circuits inflammation by decreasing the bodys production of certain proteins, and researchers hope that it will reduce lung complications and prevent deaths from COVID-19. About 6,000 patients are receiving colchicine or a placebo during the clinical trial, dubbed Colcorona, which began in March and is expected to be completed in September.

Selinexor / Kaiser Permanente: Kaiser hospitals in San Francisco, Oakland and Sacramento are studying selinexor, an anticancer drug that blocks a key protein in the cellular machinery for DNA processing, as a potential COVID-19 treatment. The drug has both antiviral and anti-inflammatory properties, and its administered orally, according to Kaisers Dr. Jacek Skarbinski. The trial aims to enroll 250 patients with severe symptoms at Kaiser and other hospitals that are participating nationwide.

VXA-COV2-1 / Vaxart, South San Francisco: The biotechnology company Vaxart is testing this drug to see if it is as effective at controlling COVID-19 as trials have shown it to be against influenza. VXA-COV2-1, the only potential vaccine in pill form, uses the genetic code of the coronavirus to trigger a defensive response in mucous membranes. The hope is that the newly fortified membranes will prevent the virus from entering the body.

Its the only vaccine (candidate) that activates the first line of defense, which is the mucosa, said Andrei Floroiu, Vaxarts chief executive, noting that intravenous vaccines kill the virus after it is inside the body. Our vaccine may prevent you from getting infected at all.

The drug was effective against influenza and norovirus in trials and appears to work on laboratory animals, Floroiu said. He expects trials of VXA-COV2-1 on humans to begin later this summer.

VaxiPatch / Verndari (Napa and UC Davis Medical Center): Napa vaccine company Verndari makes a patented adhesive patch that can deliver a vaccine instead of a shot. Now, the company is trying to make a vaccine for COVID-19 that they can administer through that patch. At UC Davis Medical Center in Sacramento, Verndari researchers are developing a potential vaccine that relies on the coronavirus spike-shaped protein. When injected into a person, the substance would ideally train their body to recognize the virus and fight it off without becoming ill.

A spokeswoman told The Chronicle that the companys preclinical tests have shown early, positive data in developing an immune response. Verndari hopes to move into the next phase of testing in the coming weeks and start clinical trials in humans this year.

If the vaccine is proved effective and safe, patients could receive it through the mail, according to company CEO Dr. Daniel Henderson. The patch would leave a temporary mark on the skin that patients could photograph and send to their doctor as proof they have taken the vaccine, Henderson has said.

Peter Fimrite and J.D. Morris are San Francisco Chronicle staff writers. Email: pfimrite@sfchronicle.com, jd.morris@sfchronicle.com Twitter: @pfimrite, @thejdmorris

See original here:
Efforts at coronavirus vaccines and treatments abound in the Bay Area - San Francisco Chronicle

Dublin, June 22, 2020 (GLOBE NEWSWIRE) -- The "Global Regenerative Medicine Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.

This report provides an in-depth analysis of the global regenerative medicine market with description of market sizing and growth. The analysis includes market by value, by product, by material and by region. Furthermore, the report also provides detailed product analysis, material analysis and regional analysis.

Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and would be driving the growth of the industry. Growth of the overall global regenerative medicine market has also been forecasted for the years 2020-2024, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Region Coverage:

Company Coverage:

Regenerative medicines emphasise on the regeneration or replacement of tissues, cells or organs of the human body to cure the problem caused by disease or injury. The treatment fortifies the human cells to heal up or transplant stem cells into the body to regenerate lost tissues or organs or to recover impaired functionality. There are three types of stem cells that can be used in regenerative medicine: somatic stem cells, embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells).

The regenerative medicine also has the capability to treat chronic diseases and conditions, including Alzheimer's, diabetes, Parkinson's, heart disease, osteoporosis, renal failure, spinal cord injuries, etc. Regenerative medicines can be bifurcated into different product type i.e., cell therapy, tissue engineering, gene therapy and small molecules and biologics. In addition, on the basis of material regenerative medicine can be segmented into biologically derived material, synthetic material, genetically engineered materials and pharmaceuticals.

The global regenerative medicine market has surged at a progressive rate over the years and the market is further anticipated to augment during the forecasted years 2020 to 2024. The market would propel owing to numerous growth drivers like growth in geriatric population, rising global healthcare expenditure, increasing diabetic population, escalating number of cancer patients, rising prevalence of cardiovascular disease and surging obese population.

Though, the market faces some challenges which are hindering the growth of the market. Some of the major challenges faced by the industry are: legal obligation and high cost of treatment. Whereas, the market growth would be further supported by various market trends like three dimensional bioprinting , artificial intelligence to advance regenerative medicine, etc.

Key Topics Covered:

1. Executive Summary

2. Introduction2.1 Regenerative Medicine: An Overview2.2 Regeneration in Humans: An Overview2.3 Expansion in Peripheral Industries of Regenerative Medicine2.4 Approval System for Regenerative Medicine Products2.5 Regenerative Medicine Segmentation

3. Global Market Analysis3.1 Global Regenerative Medicine Market: An Analysis3.1.1 Global Regenerative Medicine Market by Value3.1.2 Global Regenerative Medicine Market by Products (Cell Therapy, Tissue Engineering, Gene Therapy and Small Molecules and Biologics)3.1.3 Global Regenerative Medicine Market by Material (Biologically Derived Material, Synthetic Material, Genetically Engineered Materials and Pharmaceuticals)3.1.4 Global Regenerative Medicine Market by Region (North America, Europe, Asia Pacific and ROW)

3.2 Global Regenerative Medicine Market: Product Analysis3.2.1 Global Cell Therapy Regenerative Medicine Market by Value3.2.2 Global Tissue Engineering Regenerative Medicine Market by Value3.2.3 Global Gene Therapy Regenerative Medicine Market by Value3.2.4 Global Small Molecules and Biologics Regenerative Medicine Market by Value

3.3 Global Regenerative Medicine Market: Material Analysis3.3.1 Global Biologically Derived Material Market by Value3.3.2 Global Synthetic Material Market by Value3.3.3 Global Genetically Engineered Materials Market by Value3.3.4 Global Regenerative Medicine Pharmaceuticals Market by Value

4. Regional Market Analysis4.1 North America Regenerative Medicine Market: An Analysis4.2 Europe Regenerative Medicine Market: An Analysis4.3 Asia Pacific Regenerative Medicine Market: An Analysis4.4 ROW Regenerative Medicine Market: An Analysis

5. COVID-195.1 Impact of Covid-195.2 Response of Industry to Covid-195.3 Variation in Organic Traffic5.4 Regional Impact of COVID-19

6. Market Dynamics6.1 Growth Drivers6.1.1 Growth in Geriatric Population6.1.2 Rising Global Healthcare Expenditure6.1.3 Increasing Diabetic Population6.1.4 Escalating Number of Cancer Patients6.1.5 Rising Prevalence of Cardiovascular Disease6.1.6 Surging Obese Population6.2 Challenges6.2.1 Legal Obligation6.2.2 High Cost of Treatment6.3 Market Trends6.3.1 3D Bio-Printing6.3.2 Artificial Intelligence to Advance Regenerative Medicine

7. Competitive Landscape7.1 Global Regenerative Medicine Market Players: A Financial Comparison7.2 Global Regenerative Medicine Market Players' by Research & Development Expenditure

8. Company Profiles8.1 Bristol Myers Squibb (Celgene Corporation)8.1.1 Business Overview8.1.2 Financial Overview8.1.3 Business Strategy8.2 Medtronic Plc8.2.1 Business Overview8.2.2 Financial Overview8.2.3 Business Strategy8.3 Smith+Nephew (Osiris Therapeutics, Inc.)8.3.1 Business Overview8.3.2 Financial Overview8.3.3 Business Strategy8.4 Novartis AG8.4.1 Business Overview8.4.2 Financial Overview8.4.3 Business Strategy

For more information about this report visit https://www.researchandmarkets.com/r/w15smu

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See more here:
Outlook on the Worldwide Regenerative Medicine Industry to 2024 - Rising Global Healthcare Expenditure Presents Opportunities - GlobeNewswire

Researchstore.biz has released a new research report titled Global Canine Stem Cell Therapy Market 2020 by Company, Type and Application, Forecast to 2025 which offers a strategic evaluation of the market. The report presents prime parameters such as market size, revenue, sales analysis, and key drivers, and projection of the market by product, area, and use. The report delivers an in-depth analysis of the market with current and future trends. The report recognizes overall growth opportunities, industry drivers, obstacles, latest discoveries, and openings available for newcomers in the global Canine Stem Cell Therapy market.

Competitive Outlook:

The report further contains a competitive scenario of the major market players focusing on their sales revenue, customer demands, company profile, import/export scenario, business strategies that will help the emerging market segments in making major business decisions. In addition, their product portfolio, respective product applications, and product features have been emphasized in the report. The report also provides company shares and distribution shares data for the Canine Stem Cell Therapy market category and global corporate-level profiles of the key market participants.

DOWNLOAD FREE SAMPLE REPORT: https://www.researchstore.biz/sample-request/48453

NOTE: This report takes into account the current and future impacts of COVID-19 on this industry and offers you an in-dept analysis of Canine Stem Cell Therapy market.

The study profiles and examines leading companies and other prominent companies operating in the global Canine Stem Cell Therapy industry, covering: VETSTEM BIOPHARMA, VetMatrix, Aratana Therapeutics, Cell Therapy Sciences, Vetbiologics, Regeneus, ANIMAL CELL THERAPIES, Okyanos, Medivet Biologics, Magellan Stem Cells, Stemcellvet,

The far-reaching market study enlists a focused assessment of this business space and the regional landscape of this vertical. As per the report, the Canine Stem Cell Therapy market has established its presence across regions such as: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa)

On the basis of product, this report displays the production, revenue, price, market share, and growth rate of each type, primarily split into: Allogeneic Stem Cells, Autologous Stem cells

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share market growth rate for each application, including: Veterinary Hospitals, Veterinary Clinics, Veterinary Research Institutes

This search provides an analysis of indirect and direct sales channels, helps you to plan the right distribution strategy. The study also predicts the influence of different industry aspects on the global Canine Stem Cell Therapy market segments and regions. It delivers analysis on consumption volume, region-wise import/export analysis, and forecast Canine Stem Cell Therapy market from 2020-2025. At last, the report exhibits an analysis of leading marketing players, product specification, company profiles along with the contact details, production cost.

ACCESS FULL REPORT: https://www.researchstore.biz/report/global-canine-stem-cell-therapy-market-2020-48453

Important Aspects of Canine Stem Cell Therapy Market Report:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Researchstore.biz is a fully dedicated global market research agency providing thorough quantitative and qualitative analysis of extensive market research.Our corporate is identified by recognition and enthusiasm for what it offers, which unites its staff across the world.We are desired market researchers proving a reliable source of extensive market analysis on which readers can rely on. Our research team consist of some of the best market researchers, sector and analysis executives in the nation, because of which Researchstore.biz is considered as one of the most vigorous market research enterprises. Researchstore.biz finds perfect solutions according to the requirements of research with considerations of content and methods. Unique and out of the box technologies, techniques and solutions are implemented all through the research reports.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.researchstore.biz

Originally posted here:
Global Canine Stem Cell Therapy Market with (Covid-19) Impact Analysis: Future Development, Business Growth and Applications to 2025 - Cole of Duty

22 June 2020

CRISPRgenome editing has been successfully used to treat three patients with blood disorders in a clinical trial.

Two US patients with beta-thalassaemia and one with sickle cell disease had their bone marrow stem cells edited to produce a different form of haemoglobin, which is normally only found in fetuses and newborns.

'The results [demonstrate] that CRISPR/Cas9 gene editing has the potential to be a curative therapy for severe genetic diseases like sickle cell and beta-thalassaemia,' said Dr Reshma Kewalrami, CEO and President of Vertex, which is running the study jointly with another US pharmaceutical company, CRISPR Therapeutics.

Both sickle cell and beta-thalassaemia are caused by mutations in a gene that produces haemoglobin, the protein in red blood cells that carries oxygen throughout the body. With limited treatment options, patients are often dependent on blood transfusions.

However, the human body is able to make another form of haemoglobin, encoded in a completely separate gene, which is normally only expressed during fetal development and is switched off soon after birth.

In the clinical trial, blood stem cells were removed from the patients and a control gene that turns off the production of fetal haemoglobin was inactivated. Patients were given chemotherapy to remove remaining bone marrow stem cellsbefore they were replaced by the editedcells. The patients were then able to make fetal haemoglobin as adults.

The results of the ongoing trial, presented at the virtual Annual European Hematology Association Congress, reported that two beta-thalassaemia patients were transfusion independent at five and fifteen months after treatment, and the sickle cell patient was free from painful crises at nine months after treatment.

All three patients suffered significant side effects (from which they all recovered), but these were thought to be as a result of the chemotherapy rather than genome editing. Chemotherapy can also have long-term effects including infertility.

It is hoped that this treatment will have long-lasting and durable effects in patients with inherited blood diseases, and early clinical data appear promising. However, patients will need to be followed up throughout their lives to record any changes.

'These highly encouraging early data represent one more step toward delivering on the promise and potential of CRISPR/Cas9 therapies as a new class of potentially transformative medicines to treat serious diseases,' said Dr Samarth Kulkarni, CEO of CRISPR Therapeutics.

Read the original:
CRISPR trial shows promising results for sickle cell and thalassaemia - BioNews